Editorial: Epigenetic mechanisms and post-translational modifications as novel therapeutic targets in cancer

被引：0

作者：

Shi, Zhi ^{[1
,2
]}

Wang, Ning ^{[3
]}

Zhang, Ying-Jie ^{[4
]}

Zheng, Yi-Chao ^{[5
,6
,7
]}

机构：

[1] Jinan Univ, Coll Life Sci & Technol, Dept Cell Biol, Guangzhou, Guangdong, Peoples R China

[2] Jinan Univ, Coll Life Sci & Technol, Guangdong Prov Key Lab Bioengn Med, Inst Biomed,Natl Engn Res Ctr Genet Med,MOE Key L, Guangzhou, Guangdong, Peoples R China

[3] Univ Hong Kong, Sch Chinese Med, Hong Kong, Peoples R China

[4] Shandong Univ, Cheeloo Coll Med, MOE Key Lab Chem Biol, Dept Med Chem,Sch Pharmaceut Sci, Jinan, Peoples R China

[5] Collaborat Innovat Ctr New Drug Res & Safety Eval, Zhengzhou, Henan, Peoples R China

[6] Zhengzhou Univ, Key Lab Adv Drug Preparat Technol, Zhengzhou, Henan, Peoples R China

[7] Zhenghzou Univ, Sch Pharmaceut Sci, MOE Key Lab Henan Prov Drug Qual & Evaluat, Zhengzhou, Henan, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2022年 / 13卷

关键词：

cancer; targets; epigenetic mechanisms; post-translational modifications; methylation;

D O I：

10.3389/fphar.2022.988334

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页数：2